Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 10:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 193 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Proteinuria Clear all
Completed Phase 3 Interventional Results available

Pilot Study of ACTH in the Treatment of Immunoglobulin A (IgA) Nephropathy at High Risk of Progression

NCT02282930
View directory record Official record
Conditions
Progressive IgA Nephropathy, Proteinuria
Interventions
ACTH (Acthar) Gel
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
4
States / cities
Palo Alto, California • Jacksonville, Florida • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2019 · Synced Oct 20, 2026, 10:58 AM EDT
Active, not recruiting Not applicable Interventional

Kidney Health: Eat Well, Live Well

NCT05970341
View directory record Official record
Conditions
Chronic Kidney Diseases
Interventions
1. Welcome package, 2. Welcome information (phone or text), 3. Produce delivery + Recipes customized to produce, 4. E-gift cards to a grocery store of choice, 5. Personalized practical & emotional support through a dedicated health partner
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 20, 2026, 10:58 AM EDT
Completed Phase 4 Interventional Results available

Rituximab in Progressive Immunoglobulin A (IgA) Nephropathy

NCT00498368
View directory record Official record
Conditions
IgA Nephropathy
Interventions
Intravenous Rituximab, ACE/ARB, Omega-3 Fatty Acid Fish Oil Supplement
Drug · Dietary Supplement
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
5
States / cities
San Francisco, California • Rochester, Minnesota • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Oct 20, 2026, 10:58 AM EDT
Completed Phase 1 Interventional

A Phase 1 Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With Primary Podocyte Diseases

NCT02639260
View directory record Official record
Conditions
Kidney Disease
Interventions
N-acetyl D-mannosamine
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 24, 2023 · Synced Oct 20, 2026, 10:58 AM EDT
Completed Phase 2 Interventional Results available

Pirfenidone to Treat Kidney Disease (Focal Segmental Glomerulosclerosis)

NCT00001959
View directory record Official record
Conditions
Fibrosis, Focal Glomerulosclerosis, Kidney Failure, Nephrotic Syndrome, Proteinuria
Interventions
Pirfenidone
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 26, 2014 · Synced Oct 20, 2026, 10:58 AM EDT
Terminated Phase 2 Interventional Results available

A Study of CCX140-B in Subjects With Primary FSGS and Nephrotic Syndrome

NCT03703908
View directory record Official record
Conditions
Focal Segmental Glomerulosclerosis
Interventions
CCX140-B
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
5
States / cities
Torrance, California • Shreveport, Louisiana • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Oct 20, 2026, 10:58 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Atacicept in IgA Nephropathy

NCT02808429
View directory record Official record
Conditions
IgA Nephropathy
Interventions
Placebo, Atacicept 25 mg, Atacicept 75 mg
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
16
States / cities
Glendale, Arizona • Chula Vista, California • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2021 · Synced Oct 20, 2026, 10:58 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria

NCT05196035
View directory record Official record
Conditions
Chronic Kidney Disease, Proteinuria
Interventions
Finerenone (Kerendia, BAY94-8862), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
6 Months to 17 Years
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
10
States / cities
Palo Alto, California • San Diego, California • Hollywood, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 20, 2026, 10:58 AM EDT
Withdrawn Not applicable Interventional

Autoimmune Protocol Diet Intervention on Proteinuria in IgA Nephropathy Patients

NCT07022574
View directory record Official record
Conditions
IgA Nephropathy (IgAN)
Interventions
Low inflammation diet intervention
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Manhattan Beach, California
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 20, 2026, 10:58 AM EDT
Recruiting Phase 3 Interventional

A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria

NCT05457283
View directory record Official record
Conditions
Chronic Kidney Disease, Proteinuria, Children
Interventions
Finerenone (Kerendia, BAY94-8862)
Drug
Lead sponsor
Bayer
Industry
Eligibility
1 Year to 18 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
18
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 20, 2026, 10:58 AM EDT
Recruiting Phase 4 Interventional

Empagliflozin Treatment in Kidney Transplant Recipients

NCT06013865
View directory record Official record
Conditions
Kidney Transplant, Chronic Kidney Disease
Interventions
Empagliflozin
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
19 Years and older
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
5
States / cities
Hines, Illinois • Iowa City, Iowa • Omaha, Nebraska + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 20, 2026, 10:58 AM EDT
Terminated Phase 2 Interventional Results available

Dose-Exploration Evaluating the Efficacy and Safety of Voclosporin in Subjects With Focal Segmental Glomerulosclerosis

NCT03598036
View directory record Official record
Conditions
Focal Segmental Glomerulosclerosis
Interventions
Voclosporin
Drug
Lead sponsor
Aurinia Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
21
States / cities
Denver, Colorado • Winter Park, Florida • Lawrenceville, Georgia + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Oct 20, 2026, 10:58 AM EDT
Completed Phase 3 Interventional Results available

The Effects of Vitamin D Repletion in Vitamin D Deficient Patients With Stage 3 and 4 Chronic Kidney Disease

NCT01029002
View directory record Official record
Conditions
Chronic Renal Insufficiency, Proteinuria
Interventions
Vitamin D, Placebo
Drug · Other
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 16, 2023 · Synced Oct 20, 2026, 10:58 AM EDT
Completed Not applicable Interventional

Spironolactone for Reducing Proteinuria in Diabetic Nephropathy

NCT00498537
View directory record Official record
Conditions
Diabetic Nephropathy
Interventions
spironolactone
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 90 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 17, 2008 · Synced Oct 20, 2026, 10:58 AM EDT
Terminated Not applicable Interventional Results available

Does Thiazolidinedione Therapy Improve Endothelial Function and Preserve Renal Function

NCT00586261
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Pioglitazone, Placebo, Nitroglycerin
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 15, 2013 · Synced Oct 20, 2026, 10:58 AM EDT
Terminated Phase 4 Interventional Results available

GLP-1 Receptor Agonist Therapy and Albuminuria in Patients With Type 2 Diabetes

NCT03029351
View directory record Official record
Conditions
Type2 Diabetes, Kidney Diseases
Interventions
Exenatide Extended Release for Inj Susp 2 MG, Placebo
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Williamsville, New York
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Oct 20, 2026, 10:58 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of VIS649 for IgA Nephropathy

NCT04287985
View directory record Official record
Conditions
Immunoglobulin A Nephropathy, Glomerular Disease, IgAN
Interventions
Dose-Placebo, Low Dose-VIS649, Medium Dose-VIS649, High Dose-VIS649
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
17
States / cities
Birmingham, Alabama • Los Angeles, California • Oxnard, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 20, 2026, 10:58 AM EDT
Active, not recruiting Phase 3 Interventional

Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)

NCT06087835
View directory record Official record
Conditions
Chronic Kidney Disease With High Proteinuria
Interventions
Zibotentan/Dapagliflozin, Dapagliflozin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 95 Years
Enrollment
1,835 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
64
States / cities
Huntsville, Alabama • Sun City West, Arizona • Bakersfield, California + 55 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 20, 2026, 10:58 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of the Accuracy and Usability of the ACR | U.S. Urine Analysis Test System in the Lay User Hands

NCT04626271
View directory record Official record
Conditions
Albuminuria
Interventions
ACR | U.S. Urine Analysis Test System, URiSCAN Optima Urine Analyzer
Device
Lead sponsor
Healthy.io Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
2
States / cities
Garden City, New York • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Oct 20, 2026, 10:58 AM EDT
Terminated Phase 2 Interventional Results available

Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721

NCT02682407
View directory record Official record
Conditions
IgAN, LN, MN, C3G
Interventions
OMS721 (narsoplimab)
Biological
Lead sponsor
Omeros Corporation
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
8
States / cities
Denver, Colorado • Augusta, Georgia • Lawrenceville, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 20, 2026, 10:58 AM EDT
Recruiting Phase 2 Interventional

An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Podocyte Diseases

NCT06664814
View directory record Official record
Conditions
Focal Segmental Glomerulosclerosis, Minimal Change Disease, Membranous Nephropathy
Interventions
ManNAc
Drug
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
18 Years to 115 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 20, 2026, 10:58 AM EDT
Completed Not applicable Interventional

Facilitating Improvements in Kidney Health Using a Smartphone App Counseling Program in Patients With Diabetes

NCT03015480
View directory record Official record
Conditions
Chronic Kidney Disease, Diabetes Mellitus, Albuminuria
Interventions
Remote counseling
Behavioral
Lead sponsor
Geisinger Clinic
Other
Eligibility
21 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Danville, Pennsylvania • Wilkes-Barre, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 1, 2019 · Synced Oct 20, 2026, 10:58 AM EDT
Completed Phase 2 Interventional Results available

Effect of Atorvastatin on Endothelial Dysfunction and Albuminuria in Sickle Cell Disease

NCT01732718
View directory record Official record
Conditions
Sickle Cell Disease, Sickle Cell Nephropathy
Interventions
Atorvastatin, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 60 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 18, 2020 · Synced Oct 20, 2026, 10:58 AM EDT
Withdrawn Not applicable Interventional

Effects of Vitamin D on Renal Blood Flow, Proteinuria and Inflammation in Patients With Chronic Kidney Disease

NCT01426724
View directory record Official record
Conditions
Chronic Kidney Disease, Secondary Hyperparathyroidism
Interventions
Contrast Enhanced Ultrasonography
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 21, 2014 · Synced Oct 20, 2026, 10:58 AM EDT